{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:54:42Z","timestamp":1764510882984,"version":"3.46.0"},"reference-count":231,"publisher":"Practical Medicine Publishing House","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Oncohematology"],"abstract":"<jats:p>Advances in treatment options for patients with multiple myeloma have made a significant impact on overall survival and have helped to achieve the rates of response and duration of remission previously not unachievable with standard chemotherapy-based approaches. These improvements are due, in a large part, to the development of the novel agents, including bortezomib, thalidomide, and lenalidomide, each of which has substantial single-agent activity. Combinations of bortezomib, thalidomide, and lenalidomide with conventional agents or among each other have resulted in enhanced response rates and efficacy. However, when patients are unresponsive to immunomodulatory drugs and bortezomib, the prognosis becomes poor. A number of novel agents are being tested in multiple myeloma, but relapsed\/refractory multiple myeloma still represents a challenge and difficult area for drug development. Therefore, the new agents are needed. In addition, a large number of second- or third-generation agents are also in clinical development, such that the repertoire of available treatment options continues to expand. Such agents as carfilzomib, pomalidomide, vorinostat, panobinistat, romidepsin, perifosine, tanespimycin, bendamustine, and elotuzumab are just a few out of many exciting new compounds that are being tested in phases I, II, or III of clinical trials for relapsed patients. This review covers the new strategies, based on clinical trials and our own data and intended for optimizing treatment outcomes in relapsed\/refractory multiple myeloma. We describe the various classes of novel drugs under investigation and discuss the pros and cons of the data obtained in preclinical and clinical studies. The adverse effects of the new drugs are presented in detail.<\/jats:p>","DOI":"10.21320\/2500-2139-2014-7-2-137-174","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:41:45Z","timestamp":1751352105000},"page":"137-174","source":"Crossref","is-referenced-by-count":1,"title":["Management of relapsed and refractory multiple myeloma: literature review and our data. Part III","\u041c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u043c\u0438\u0435\u043b\u043e\u043c\u0430 (\u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u0440\u0435\u0446\u0438\u0434\u0438\u0432\u043e\u0432 \u0438 \u0440\u0435\u0444\u0440\u0430\u043a\u0442\u0435\u0440\u043d\u044b\u0445 \u0444\u043e\u0440\u043c): \u043e\u0431\u0437\u043e\u0440 \u043b\u0438\u0442\u0435\u0440\u0430\u0442\u0443\u0440\u044b \u0438 \u0441\u043e\u0431\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0435 \u0434\u0430\u043d\u043d\u044b\u0435. \u0427\u0430\u0441\u0442\u044c III"],"prefix":"10.21320","volume":"7","author":[{"given":"S. S.","family":"Bessmeltsev","sequence":"first","affiliation":[{"name":"Russian Research Institute of Hematology and Transfusiology, FMBA, Saint Petersburg, Russian Federation"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u043e-\u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u0442\u0435\u043b\u044c\u0441\u043a\u0438\u0439 \u0438\u043d\u0441\u0442\u0438\u0442\u0443\u0442 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438 \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u0438 \u0424\u0435\u0434\u0435\u0440\u0430\u043b\u044c\u043d\u043e\u0433\u043e \u043c\u0435\u0434\u0438\u043a\u043e-\u0431\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0430\u0433\u0435\u043d\u0442\u0441\u0442\u0432\u0430\u00bb, \u0421\u0430\u043d\u043a\u0442-\u041f\u0435\u0442\u0435\u0440\u0431\u0443\u0440\u0433, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8834","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"key":"21195","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0410\u0431\u0434\u0443\u043b\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c. \u041c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u043c\u0438\u0435\u043b\u043e\u043c\u0430. \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0439 \u0432\u0437\u0433\u043b\u044f\u0434 \u043d\u0430 \u043f\u0440\u043e\u0431\u043b\u0435\u043c\u0443. \u0410\u043b\u043c\u0430\u0442\u044b: \u041a\u043e\u0441\u0442\u0430, 2007. [Bessmeltsev S.S., Abdulkadyrov K.M. Mnozhestvennaya miyeloma. Sovremennyy vzglyad na problemu (Multiple myeloma. Current view of the problem). Almaty: Kosta, 2007.]"},{"key":"21196","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2004.1.237"},{"key":"21197","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.578"},{"key":"21198","doi-asserted-by":"publisher","DOI":"10.1517\/14728210802676278"},{"key":"21199","unstructured":"\u0420\u0443\u0433\u0430\u043b\u044c \u0412.\u0418., \u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0421\u0435\u043c\u0435\u043d\u043e\u0432\u0430 \u041d.\u042e. \u0438 \u0434\u0440. \u0421\u0442\u0440\u0443\u043a\u0442\u0443\u0440\u043d\u044b\u0435 \u043e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u043f\u0430\u0440\u0435\u043d\u0445\u0438\u043c\u044b \u0438 \u0441\u0442\u0440\u043e\u043c\u044b \u043a\u043e\u0441\u0442\u043d\u043e\u0433\u043e \u043c\u043e\u0437\u0433\u0430 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u043e\u0439. Medline.ru. 2012; 13: 515\u201323. [Rugal V.I., Bessmeltsev S.S., Semenova N.Yu., et al. Structural features of bone marrow parenchyma and stroma in patients with multiple myeloma. Medline.ru. 2012; 13: 515\u201323. (In Russ.)]."},{"key":"21200","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.342.3798324"},{"key":"21201","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-357038"},{"key":"21202","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0493"},{"key":"21203","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0037"},{"key":"21204","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"21205","unstructured":"Lonial S. Treatment of relapsed and refractory multiple myeloma. Hematol. Educ. Ann. Congr. Eur. Hematol. Assoc. 2013; 7: 216\u201326."},{"key":"21206","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.15"},{"key":"21207","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"21208","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405016"},{"key":"21209","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07303.x"},{"key":"21210","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299529"},{"key":"21211","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.489"},{"key":"21212","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.310"},{"key":"21213","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.180"},{"key":"21214","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.06.002"},{"key":"21215","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07984.x"},{"key":"21216","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3869"},{"key":"21217","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.303"},{"key":"21218","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.953.953"},{"key":"21219","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.8100"},{"key":"21220","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"21221","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-1-8"},{"key":"21222","unstructured":"Gertz M.A., Garton J.P., Greipp P.R., Witzig T.E., Kyle R.A. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995; 9: 2115\u20138."},{"key":"21223","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102104"},{"key":"21224","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.65"},{"key":"21225","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509056859"},{"key":"21226","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1227"},{"key":"21227","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200003)63:3<125::AID-AJH3>3.0.CO;2-S"},{"key":"21228","unstructured":"Munshi N., Desikan K., Jagannath S. et al. Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation. Blood 1996; 88: Abstract 586a."},{"key":"21229","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.51"},{"key":"21230","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0410\u0431\u0434\u0443\u043b\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c. \u0412\u043e\u0437\u043c\u043e\u0436\u043d\u043e\u0441\u0442\u0438 \u043f\u0440\u0438\u043c\u0435\u043d\u0435\u043d\u0438\u044f \u043f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u043d\u044b\u0445 \u043d\u0438\u0442\u0440\u043e\u0437\u043e\u043c\u0435\u0442\u0438\u043b\u043c\u043e\u0447\u0435\u0432\u0438\u043d\u044b \u0438 \u0432\u0435\u043f\u0435\u0437\u0438\u0434\u0430 \u0432 \u0445\u0438\u043c\u0438\u043e\u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043c\u043d\u043e\u0436\u0435- \u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b \u0438 \u0437\u043b\u043e\u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u043b\u0438\u043c\u0444\u043e\u043c. \u0421\u043e\u0432\u0440. \u043e\u043d\u043a\u043e\u043b. 2002; 1: 25\u20139. [Bessmeltsev S.S., Abdulkadyrov K.M. Potentials use of nitrosourea derivatives and VePesid in chemotherapy for multiple myeloma and malignant lymphomas. Sovr. onkol., 2002; 1: 25\u20139. (In Russ.)]."},{"key":"21231","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02082.x"},{"key":"21232","unstructured":"Abdulkadyrov K.M., Bessmeltsev S.S. Use of VCAP, ARA-COP and VAD schedules in treatment of patients with multiple myeloma (MM). XVI International Cancer Congress. New Delhi (India), 1994: Abstract NA-02807."},{"key":"21233","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0410\u0431\u0434\u0443\u043b\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c., \u0420\u0443\u043a\u0430\u0432\u0438\u0446\u044b\u043d \u041e.\u0410. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432- \u043d\u043e\u0441\u0442\u044c \u043d\u0435\u043a\u043e\u0442\u043e\u0440\u044b\u0445 \u043f\u0440\u043e\u0433\u0440\u0430\u043c\u043c \u043f\u043e\u043b\u0438\u0445\u0438\u043c\u0438\u043e\u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043f\u0440\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u043e\u0439. T\u0435\u0440. \u0430\u0440\u0445. 1998; 3: 46\u20139. [Bessmeltsev S.S., Abdulkadyrov K.M., Rukavitsyn O.A. Efficacy of some polychemotherapy programs in management of patient with multiple myeloma. Ter. arkh., 1998; 3: 46\u20139. (In Russ.)]."},{"key":"21234","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0421\u0442\u0435\u043b\u044c\u043c\u0430\u0448\u0435\u043d\u043a\u043e \u041b.\u0412. \u0421\u0440\u0430\u0432\u043d\u0438\u0442\u0435\u043b\u044c\u043d\u0430\u044f \u043e\u0446\u0435\u043d\u043a\u0430 \u0440\u0430\u0437- \u043b\u0438\u0447\u043d\u044b\u0445 \u043c\u0435\u0442\u043e\u0434\u043e\u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0441 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u043e\u0439. \u042d\u0444\u0444\u0435\u0440\u0435\u043d\u0442. \u0442\u0435\u0440. 2000; 2: 54\u201363. [Bessmeltsev S.S., Stelmashenko L.V. Comparative evaluation of various therapeutic methods in patients with multiple myeloma. Efferent. ter. 2000; 2: 54\u201363. (In Russ.)]."},{"key":"21235","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10561"},{"key":"21236","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4278.bloodjournal84124278"},{"key":"21237","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219120-00005"},{"key":"21238","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0410\u0431\u0434\u0443\u043b\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c. a-2\u0430-\u0438\u043d\u0442\u0435\u0440\u0444\u0435\u0440\u043e\u043d (\u0420\u0435\u0430\u0444\u0435\u0440\u043e\u043d) \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u043e\u0439. \u0412\u043e\u043f\u0440. \u043e\u043d\u043a\u043e\u043b. 1999; 4: 393\u20137. [Bessmeltsev S.S., Abdulkadyrov K.M. a-2a-interferon (Reaferon) in management of patients with multiple myeloma. Vopr. onkol., 1999; 4: 393\u20137. (In Russ.)]."},{"key":"21239","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.9942643.x"},{"key":"21240","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199512000-00003"},{"key":"21241","unstructured":"Peest D. The role of alpha-interferon in multiple myeloma. Pathol. Biol. (Paris) 1999; 47(2): 172\u20137."},{"key":"21242","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0410\u0431\u0434\u0443\u043b\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0446\u0438\u043a\u043b\u043e\u0441\u043f\u043e\u0440\u0438\u043d\u0430 \u0410 \u043f\u0440\u0438 \u0440\u0435\u0444\u0440\u0430\u043a\u0442\u0435\u0440\u043d\u044b\u0445 \u0444\u043e\u0440\u043c\u0430\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b \u0438 \u0440\u0435\u0446\u0438\u0434\u0438\u0432\u0435 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f. \u0410\u043a\u0442\u0443\u0430\u043b\u044c\u043d\u044b\u0435 \u0432\u043e\u043f\u0440\u043e\u0441\u044b \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438 \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u0438. \u041c\u0430\u0442-\u043b\u044b \u0420\u043e\u0441. \u043d\u0430\u0443\u0447.-\u043f\u0440\u0430\u043a\u0442. \u043a\u043e\u043d\u0444., \u043f\u043e\u0441\u0432\u044f\u0449\u0435\u043d\u043d\u043e\u0439 70-\u043b\u0435\u0442\u0438\u044e \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0433\u043e \u041d\u0418\u0418 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438 \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u0438, \u0421\u0430\u043d\u043a\u0442-\u041f\u0435\u0442\u0435\u0440\u0431\u0443\u0440\u0433, 18\u201320 \u0438\u044e\u043d\u044f 2002 \u0433. \u0421\u041f\u0431., 2002: 98. [Bessmeltsev S.S., Abdulkadyrov K.M. Effektivnost tsiklosporina A pri refrakternykh formakh mnozhestvennoy mielomy i retsidive zabolevaniya. Aktualnye voprosy gematologii i transfuziologii. Mat-ly Ros. nauch.-prakt. konf., posvyashchennoy 70-letiyu Rossiyskogo NII gematologii i transfuziologii, (Efficacy of cyclosporine A in refractory forms and relapses of multiple myeloma. Current issues in hematology and transfusiology. In: Materials of Rus. scient.-pract. conference dedicated to 70th anniversary of the Russian Research Institute of Hematology and Transfusiology. Saint Petersburg, June 18-20, 2002, St. Petersburg, 2002: 98.]"},{"key":"21243","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0410\u0431\u0434\u0443\u043b\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c. \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0435 \u043f\u0440\u0438\u043d\u0446\u0438\u043f\u044b \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u043e\u0439. \u0413\u0435\u043c\u0430\u0442\u043e\u043b. i \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437i\u043e\u043b.: \u0444\u0443\u043d\u0434. \u0442\u0430 \u043f\u0440\u0438\u043a\u043b\u0430\u0434. \u043f\u0438\u0442. \u041c\u0430\u0442-\u043b\u044b \u043d\u0430\u0443\u0447.-\u043f\u0440\u0430\u043a\u0442. \u043a\u043e\u043d\u0444., \u041a\u0438\u0435\u0432, 13\u201314 \u043e\u043a\u0442\u044f\u0431\u0440\u044f 2005 \u0433. \u041a\u0438\u0435\u0432, 2005: 21\u20133. [Bessmeltsev S.S., Abdulkadyrov K.M. Sovremennye printsipy lecheniya bolnykh mnozhestvennoy mielomoy. Gematol. i transfuziol.: fund. ta priklad. pit. Mat-ly nauch.-prakt. konf. (Current principles of management of patients with multiple myeloma. Hematol. and transfuiol.: fund. and pract. issues. In: Material of scient.-pract. conference, Kiev, October 13-14, 2005), Kiev, 2005: 21\u20133.]"},{"key":"21244","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:2:87"},{"key":"21245","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200008000-00011"},{"key":"21246","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001628158"},{"key":"21247","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"21248","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"21249","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.34"},{"key":"21250","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01729.x"},{"key":"21251","unstructured":"Neben K., Moehler T., Benner A. et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin. Cancer Res. 202; 8: 3377\u201380."},{"key":"21252","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05914.x"},{"key":"21253","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.044271"},{"key":"21254","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6689"},{"key":"21255","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.875"},{"key":"21256","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011132808904"},{"key":"21257","unstructured":"Weber D. Thalidomide: a wide spectrum of activity. Myeloma Focus. Newslett. Multiple Myel. Res. Found. 2002; IV: 4."},{"key":"21258","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200403"},{"key":"21259","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3563.3563"},{"key":"21260","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200401"},{"key":"21261","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00610.x"},{"key":"21262","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:4:219"},{"key":"21263","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05521.x"},{"key":"21264","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200326"},{"key":"21265","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04473.x"},{"key":"21266","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403322"},{"key":"21267","unstructured":"Offidani M., Corvatta L., Marconi M. et al. Low dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed\/ refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006; 91: 133\u20136."},{"key":"21268","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.889"},{"key":"21269","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-02-0080"},{"key":"21270","doi-asserted-by":"crossref","unstructured":"Pineda-Roman M., Zangari M., van Rhee F. et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22: 1419\u201327.","DOI":"10.1038\/leu.2008.99"},{"key":"21271","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0220-3"},{"key":"21272","doi-asserted-by":"crossref","unstructured":"Reece D.E., Rodriguez G.P., Chen C. et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J. Clin. Oncol. 2008; 26(29): 4777\u201383.","DOI":"10.1200\/JCO.2007.14.2372"},{"key":"21273","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4918"},{"key":"21274","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0996"},{"key":"21275","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"key":"21276","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.412.412"},{"key":"21277","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"21278","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3550.3550"},{"key":"21279","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"21280","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141614"},{"key":"21281","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3552.3552"},{"key":"21282","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3554.3554"},{"key":"21283","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"21284","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007309563"},{"key":"21285","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3547.3547"},{"key":"21286","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.3597.3597"},{"key":"21287","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc053530"},{"key":"21288","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3888.3888"},{"key":"21289","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3548.3548"},{"key":"21290","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl313"},{"key":"21291","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.408.408"},{"key":"21292","unstructured":"Knop S., Gerecke C., Topp M.S. et al. RAD (Revlimid, Adriamycin, Dex) is a new treatment regimen for relapsed multiple myeloma. Haematologica 2007; 92(s2): Abstract PO-658."},{"key":"21293","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06538.x"},{"key":"21294","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1874.1874"},{"key":"21295","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2679"},{"key":"21296","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.8536"},{"key":"21297","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u041a\u0430\u0440\u044f\u0433\u0438\u043d\u0430 \u0415.\u0412., \u0421\u0442\u0435\u043b\u044c\u043c\u0430\u0448\u0435\u043d\u043a\u043e \u041b.\u0412. \u0438 \u0434\u0440. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u043b\u0435\u043d\u0430\u043b\u0438\u0434\u043e\u043c\u0438\u0434\u0430 \u043f\u0440\u0438 \u0440\u0435\u0444\u0440\u0430\u043a\u0442\u0435\u0440\u043d\u044b\u0445\/\u0440\u0435\u0446\u0438\u0434\u0438\u0432\u0438\u0440\u0443\u044e\u0449\u0438\u0445 \u0444\u043e\u0440\u043c\u0430\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. \u041e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f 2012; 1: 6\u201314. [Bessmeltsev S.S., Karyagina Ye.V., Stelmashenko L.V. et al. Lenalidomide efficacy in refractory\/relapsing forms of multiple myeloma. Onkogematologiya 2012; 1: 6\u201314. (In Russ.)]."},{"key":"21298","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"21299","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"21300","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"key":"21301","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07359.x"},{"key":"21302","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"21303","doi-asserted-by":"crossref","unstructured":"Richardson P.G., Sonneveld P., Schuster M. et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110(10): 3557\u201360.","DOI":"10.1182\/blood-2006-08-036947"},{"key":"21304","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.6533"},{"key":"21305","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0135-z"},{"key":"21306","unstructured":"Jagannath S., Richardson P.G., Barlogie B. et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/ or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91: 929\u201334."},{"key":"21307","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.11.004"},{"key":"21308","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07409.x"},{"key":"21309","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.52.149"},{"key":"21310","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u041a\u0430\u0440\u044f\u0433\u0438\u043d\u0430 \u0415.\u0412., \u0421\u0442\u0435\u043b\u044c\u043c\u0430\u0448\u0435\u043d\u043a\u043e \u041b.\u0412. \u0438 \u0434\u0440. \u0411\u043e\u0440\u0442\u0435\u0437\u043e\u043c\u0438\u0431 (\u0412\u0435\u043b\u043a\u0435\u0439\u0434) \u0432 \u043a\u043e\u043c\u0431\u0438\u043d\u0430\u0446\u0438\u0438 \u0441 \u0434\u0435\u043a\u0441\u0430\u043c\u0435\u0442\u0430\u0437\u043e\u043d\u043e\u043c \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0440\u0435\u0444\u0440\u0430\u043a\u0442\u0435\u0440\u043d\u044b\u0445\/\u0440\u0435\u0446\u0438\u0434\u0438\u0432\u0438\u0440\u0443\u044e\u0449\u0438\u0445 \u0444\u043e\u0440\u043c \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. \u0420\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u0437\u0430\u043a\u043b\u044e\u0447\u0438\u0442\u0435\u043b\u044c\u043d\u043e\u0433\u043e \u0430\u043d\u0430\u043b\u0438\u0437\u0430. \u041a\u043b\u0438\u043d. \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b. 2009; 2(3): 236\u201344. [Bessmeltsev S.S., Karyagina Ye.V., Stelmashenko L.V., et al. Bortezomib (Velcade) in combination with dexamethasone in therapy for refractory\/relapsing forms of multiple myeloma (final analysis results). Klin. onkogematol. 2009; 2(3): 236\u201344. (In Russ.)]."},{"key":"21311","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"},{"key":"21312","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-403733"},{"key":"21313","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13285"},{"key":"21314","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"21315","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u041a\u0430\u0440\u044f\u0433\u0438\u043d\u0430 \u0415.\u0412., \u0421\u0442\u0435\u043b\u044c\u043c\u0430\u0448\u0435\u043d\u043a\u043e \u041b.\u0412. \u0438 \u0434\u0440. \u0411\u043e\u0440\u0442\u0435\u0437\u043e\u043c\u0438\u0431 (\u0432\u0435\u043b\u043a\u0435\u0439\u0434) \u0438 \u0434\u0435\u043a\u0441\u0430\u043c\u0435\u0442\u0430\u0437\u043e\u043d \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0440\u0435\u0444\u0440\u0430\u043a\u0442\u0435\u0440\u043d\u044b\u0445\/\u0440\u0435\u0446\u0438\u0434\u0438\u0432\u0438\u0440\u0443\u044e\u0449\u0438\u0445 \u0444\u043e\u0440\u043c \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b (\u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u043f\u0440\u043e\u043c\u0435\u0436\u0443\u0442\u043e\u0447\u043d\u043e\u0433\u043e \u0430\u043d\u0430\u043b\u0438\u0437\u0430). \u0412\u0435\u0441\u0442\u043d. \u0433\u0435\u043c\u0430\u0442\u043e\u043b. 2008; 4: 14\u201322. [Bessmeltsev S.S., Karyagina Ye.V., Stelmashenko L.V., et al. Bortezomib (Velcade) in combination with dexamethasone in therapy for refractory\/relapsing forms of multiple myeloma (interim analysis results). Vest. gematol. 2008; 4: 14\u201322. (In Russ.)]."},{"key":"21316","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"21317","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2911"},{"key":"21318","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"21319","unstructured":"Spencer A., Hajek R., Nagler A. et al. Doxil + velcade in previously treated high risk myeloma. Haematologica 2007; 92: 162. 126. San Miguel J., Hajek R., Nagler A. et al. Doxil + velcade in previously treated \u00b3 65y myeloma pts. Haematologica 2007; 92: 159."},{"key":"21320","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn018"},{"key":"21321","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.99"},{"key":"21322","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500272721"},{"key":"21323","unstructured":"Garderet L., Iacobelli S., Moreau P. et al. Bortezomib (VELCADE)-thalidomide-dexamethasone (VTD) is superior to thalidomide-dexamethasone (TD) in patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation [abstract]. Haematologica 2011; 96(s2): 420\u20131. Abstract 1008."},{"key":"21324","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.2372"},{"key":"21325","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.2549.2549"},{"key":"21326","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.209.209"},{"key":"21327","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.363.363"},{"key":"21328","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.235"},{"key":"21329","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.2553.2553"},{"key":"21330","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099"},{"key":"21331","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.1742.1742"},{"key":"21332","unstructured":"Wolf J., Richardson P.G., Schuster M. et al. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin. Adv. Hematol. Oncol. 2008; 6: 755\u20139."},{"key":"21333","unstructured":"Hrusovsky I., Emmerich B., Enhgelhardt M. et al. Response to bortezomib retreatment is determined by duration of preceding treatment free interval \u2014 results from a retrospective multicenter survey. Haematologica 2008; 93(Suppl. 1): 259. Abstract 0645."},{"key":"21334","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-036947"},{"key":"21335","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.016"},{"key":"21336","doi-asserted-by":"publisher","DOI":"10.1159\/000322866"},{"key":"21337","unstructured":"Petrucci M.T., Blau I., Corradini P. et al. Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from RETRIEVE, a prospective international phase 2 study. Haematologica 2010; 95(s2): 152. Abstract 0377."},{"key":"21338","unstructured":"\u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421., \u0421\u0442\u0435\u043b\u044c\u043c\u0430\u0448\u0435\u043d\u043a\u043e \u041b.\u0412., \u041a\u0430\u0440\u044f\u0433\u0438\u043d\u0430 \u0415.\u0412. \u0438 \u0434\u0440. \u041b\u0435\u0447\u0435\u043d\u0438\u0435 \u0440\u0435\u0444\u0440\u0430\u043a\u0442\u0435\u0440\u043d\u044b\u0445\/\u0440\u0435\u0446\u0438\u0434\u0438\u0432\u0438\u0440\u0443\u044e\u0449\u0438\u0445 \u0444\u043e\u0440\u043c \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. Medline. ru. 2011; 12: 763\u201380. [Bessmeltsev S.S., Stelmashenko L.V., Karyagina Ye.V., et al. Management of refractory\/relapsing forms of multiple myeloma. Medline.ru. 2011; 12: 763\u201380. (In Russ.)]."},{"key":"21339","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2317"},{"key":"21340","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4525"},{"key":"21341","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.567265"},{"key":"21342","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S34498"},{"key":"21343","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.052"},{"key":"21344","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07013.x"},{"key":"21345","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.634.634"},{"key":"21346","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-450742"},{"key":"21347","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.812.812"},{"key":"21348","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-452375"},{"key":"21349","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.201.201"},{"key":"21350","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.8016"},{"key":"21351","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.LBA-6.LBA-6"},{"key":"21352","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.8510"},{"key":"21353","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.446.446"},{"key":"21354","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.74.74"},{"key":"21355","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.727.727"},{"key":"21356","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.77.77"},{"key":"21357","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S13838"},{"key":"21358","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-446534"},{"key":"21359","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3877.3877"},{"key":"21360","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.08.003"},{"key":"21361","doi-asserted-by":"crossref","unstructured":"Vij R., Wang M., Kaufman J.L. et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma. Blood 2012; 119: 5661\u201370.","DOI":"10.1182\/blood-2012-03-414359"},{"key":"21362","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.985.985"},{"key":"21363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"21364","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8000"},{"key":"21365","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414359"},{"key":"21366","unstructured":"Jakubowiak A.J., Martin T., Singhal S. et al. Responses to single-agent carfilzomib (CFZ) are not affected by cytogenetics in patients (pts) with relapsed and refractory multiple myeloma. Ann. Oncol. 2011; 22(Suppl. 4): iv122. Abstract 117."},{"key":"21367","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1876.1876"},{"key":"21368","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.29"},{"key":"21369","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.304.304"},{"key":"21370","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.8025"},{"key":"21371","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-415"},{"key":"21372","doi-asserted-by":"publisher","DOI":"10.2174\/156800911794519716"},{"key":"21373","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.302.302"},{"key":"21374","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.301.301"},{"key":"21375","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.816.816"},{"key":"21376","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3434"},{"key":"21377","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205664"},{"key":"21378","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.3691.3691"},{"key":"21379","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.1164.1164"},{"key":"21380","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1869.1869"},{"key":"21381","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070779"},{"key":"21382","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.2774.2774"},{"key":"21383","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.8542"},{"key":"21384","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1855.1855"},{"key":"21385","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.2781.2781"},{"key":"21386","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3852.3852"},{"key":"21387","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.8012"},{"key":"21388","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481325"},{"key":"21389","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.1167.1167"},{"key":"21390","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.e19508"},{"key":"21391","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.3698.3698"},{"key":"21392","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-10-1247"},{"key":"21393","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2850"},{"key":"21394","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3886.3886"},{"key":"21395","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3890.3890"},{"key":"21396","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.305.305"},{"key":"21397","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.306.306"},{"key":"21398","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.480.480"},{"key":"21399","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1710.1710"},{"key":"21400","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.4061.4061"},{"key":"21401","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.150.5.975"},{"key":"21402","doi-asserted-by":"publisher","DOI":"10.1038\/359540a0"},{"key":"21403","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1860.1860"},{"key":"21404","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.449.449"},{"key":"21405","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"21406","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783X-15-1-13"},{"key":"21407","unstructured":"Knop S., Straka C., Haen M. et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005; 90: 1287\u20138."},{"key":"21408","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07076.x"},{"key":"21409","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701694194"},{"key":"21410","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M801291200"},{"key":"21411","doi-asserted-by":"publisher","DOI":"10.1379\/CSC-99r.1"},{"key":"21412","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1417"},{"key":"21413","unstructured":"Chauhan D., Li G., Shringarpure R. et al. Blockade of Hsp27 overcomes bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003; 63: 6174\u20137."},{"key":"21414","doi-asserted-by":"crossref","unstructured":"Badros A.Z., Richardson P.G., Albitar M. et al. Tanespimycin + bortezomib in relapsed\/refractory myeloma patients: results from the Time-2 study. Blood 2009; 114: 1871 (ASH abstract).","DOI":"10.1182\/blood.V114.22.1871.1871"},{"key":"21415","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.2890.2890"},{"key":"21416","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1871.1871"},{"key":"21417","unstructured":"Lonial S., Jagannath S. Monoclonal antibodies in the treatment of multiple myeloma. Haematologica. 13th International Myeloma Workshop, Paris, France, May 3\u20136, 2011; Abstract Book: S22\u20133."},{"key":"21418","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.73.73"},{"key":"21419","unstructured":"\u0425\u0430\u0440\u0447\u0435\u043d\u043a\u043e \u041c.\u0424., \u0411\u0435\u0441\u0441\u043c\u0435\u043b\u044c\u0446\u0435\u0432 \u0421.\u0421. \u0417\u043d\u0430\u0447\u0435\u043d\u0438\u0435 \u043f\u0440\u043e\u0442\u0435\u043e\u0433\u043b\u0438\u043a\u0430\u043d\u043e\u0432 \u0432 \u043f\u0430\u0442\u043e\u0433\u0435\u043d\u0435\u0437\u0435 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. Medline.ru. 2010; 11: 404\u201323. [Kharchenko M.F., Bessmeltsev S.S. Significance of proteoglycans in pathogenesis of multiple myeloma. Medline.ru. 2010; 11: 404\u201323. (In Russ.)]."},{"key":"21420","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01542.x"},{"key":"21421","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"21422","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"21423","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0483"},{"key":"21424","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8020"},{"key":"21425","unstructured":"Richardson P.G., Jagannath S., Moreau P. et al. A phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma: update results: 54th American Society of Hematology Annual Meeting and Exposition; December 8\u201311, 2012; Atlanta, GA."}],"container-title":["Clinical Oncohematology"],"original-title":[],"link":[{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/593\/550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/593\/550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:18:36Z","timestamp":1764501516000},"score":1,"resource":{"primary":{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/view\/593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":231,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.21320\/2500-2139-2014-7-2-137-174","relation":{},"ISSN":["2500-2139","1997-6933"],"issn-type":[{"type":"electronic","value":"2500-2139"},{"type":"print","value":"1997-6933"}],"subject":[],"published":{"date-parts":[[2014,4,1]]}}}